Expression of human recombinant plasminogen activators enhances invasion and experimental metastasis of H-ras-transformed NIH 3T3 cells
- PMID: 2747645
- PMCID: PMC363007
- DOI: 10.1128/mcb.9.5.2133-2141.1989
Expression of human recombinant plasminogen activators enhances invasion and experimental metastasis of H-ras-transformed NIH 3T3 cells
Abstract
The gene transfer technique was used to examine the role of plasminogen activator (PA) in the invasive and metastatic behavior of tumorigenic cells. H-ras-transformed NIH 3T3 clonal cells producing a very low level of PA were generated and further transfected with an expression plasmid containing a cDNA sequence encoding either the urokinase-type or the tissue-type human PA. Compared with the parental transformed cells, clonal cells expressing high levels of both types of recombinant PA invaded more rapidly through a basement membrane reconstituted in vitro. Furthermore, cells expressing high levels of recombinant urokinase-type PA also caused a higher incidence of pulmonary metastatic lesions after intravenous injection into nude mice. Both activities were reduced by the serine proteinase inhibitor EACA; invasion was also suppressed by antibodies blocking the activity of human PAs and by the synthetic collagenase inhibitor SC-44463. These findings provide direct genetic evidence for a causal role of PA in invasive and metastatic activities.
Similar articles
-
T24 HRAS transformed NIH/3T3 mouse cells (GhrasT-NIH/3T3) in serial tumorigenic in vitro/in vivo passages give rise to increasingly aggressive tumorigenic cell lines T1-A and T2-A and metastatic cell lines T3-HA and T4-PA.Exp Cell Res. 2016 Jan 1;340(1):1-11. doi: 10.1016/j.yexcr.2015.07.029. Epub 2015 Aug 5. Exp Cell Res. 2016. PMID: 26254261
-
Tumorigenicity of EJ-ras oncogene transformed NIH 3T3 cells and expression of plasminogen activators.Cell Biol Int Rep. 1990 Jun;14(6):527-42. doi: 10.1016/0309-1651(90)91180-c. Cell Biol Int Rep. 1990. PMID: 2164452
-
Role of mitogen-activated protein kinases and c-Jun/AP-1 trans-activating activity in the regulation of protease mRNAs and the malignant phenotype in NIH 3T3 fibroblasts.J Biol Chem. 1999 Jan 8;274(2):801-13. doi: 10.1074/jbc.274.2.801. J Biol Chem. 1999. PMID: 9873019
-
The relationship of plasminogen activators and oncogenes to tumour invasion.Eur J Surg Oncol. 1990 Feb;16(1):54-9. Eur J Surg Oncol. 1990. PMID: 2155139 Review.
-
Modulation of the malignant phenotype with the urokinase-type plasminogen activator and the type I plasminogen activator inhibitor.Cell Differ Dev. 1990 Dec 2;32(3):277-85. doi: 10.1016/0922-3371(90)90040-4. Cell Differ Dev. 1990. PMID: 2129155 Review.
Cited by
-
Soluble factors released by the target organ enhance the urokinase-type plasminogen activator activity of metastatic tumor cells.Clin Exp Metastasis. 1991 Jan-Feb;9(1):51-6. doi: 10.1007/BF01831709. Clin Exp Metastasis. 1991. PMID: 2015717
-
Tumoral invasion in the central nervous system.J Neurooncol. 1994;18(2):111-21. doi: 10.1007/BF01050417. J Neurooncol. 1994. PMID: 7964974 Review.
-
The proteinase activated receptor-2 (PAR-2) mediates mitogenic responses in human vascular endothelial cells.J Clin Invest. 1996 Apr 1;97(7):1705-14. doi: 10.1172/JCI118597. J Clin Invest. 1996. PMID: 8601636 Free PMC article.
-
The plasminogen-plasmin system in malignancy.Cancer Metastasis Rev. 1992 Nov;11(3-4):291-311. doi: 10.1007/BF01307184. Cancer Metastasis Rev. 1992. PMID: 1423820 Review.
-
The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy.EMBO J. 1994 Sep 1;13(17):3983-91. doi: 10.1002/j.1460-2075.1994.tb06714.x. EMBO J. 1994. PMID: 8076594 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials